COSMOS provides evidence of the association of serum phosphorus, calcium and PTH and mortality, and suggests survival benefits of controlling chronic kidney disease-mineral and bone disorder biochemical parameters in CKD5D patients.
Our data suggest that Glu-OCN-controlled production of Delta like-1 (DLK1) by pancreatic β cells acts as a negative feedback mechanism to counteract the stimulatory effects of insulin on osteoblast production of Glu-OCN, a potential mechanism … Leer más
JAMA Intern Med. Published online April 13, 2015. doi:10.1001/jamainternmed.2015.0747. In this group of frail elderly women with osteoporosis, 1 dose of zoledronic acid improved BMD over 2 years. The clinical importance of nonsignificant increases in … Leer más
The switch from tenofovir to abacavir seems to induce a positive effect on bone tissue, since bone turnover markers decreased. In addition, circulating sclerostin levels increased, a change associated with improved bone properties.
The tissue-selective estrogen complex (TSEC) combines bazedoxifene and conjugated estrogens and is designed not only to improve menopausal symptoms and vulvovaginal atrophy but also to prevent bone loss. Therefore, it maintains the benefits of estrogen … Leer más
Sequential antiresorptive therapy is recommended to maintain drug increases in bone mass and support secondary mineralization of the newly formed bone. Combination therapies of antiresorptives and anabolic agents have shown a significant increase in bone … Leer más
Our study is the first to demonstrate that reference point indentation is sensitive enough to reflect changes in cortical bone indentation following treatment with osteoporosis therapies in patients newly exposed to glucocorticoids.
J Clin Invest. 2015 Apr;125(4):1509-22. doi: 10.1172/JCI77716. Epub 2015 Mar 9. Together, our results indicate that miR-188 is a key regulator of the age-related switch between osteogenesis and adipogenesis of BMSCs and may represent a … Leer más
JAMA Intern Med. Published online April 13, 2015. doi:10.1001/jamainternmed.2015.0757 In this issue of JAMA Internal Medicine, Greenspan and colleagues1 present intriguing data on zoledronic acid, one of the most potent drugs in the bisphosphonate family—if … Leer más
JAMA. 2015 Apr 14;313(14):1467-1468. doi: 10.1001/jama.2015.1064. This JAMA Clinical Guidelines Synopsis article summarizes the most recent National Osteoporosis Foundation guidelines on screening older men and postmenopausal women for osteoporosis. Autor: Altkorn D, Cifu AS.
